Practice-changing results reported for Revolution Medicines pancreatic cancer drug

Practice-changing results reported for Revolution Medicines pancreatic cancer drug

Revolution Medicines' daraxonrasib, a targeted oral therapy for pancreatic cancer, roughly doubled patient survival versus standard chemotherapy in a Phase trial presented at ASCO 2026 and published simultaneously in the New England Journal of Medicine. For biotech and oncology investors, this is the first meaningful efficacy signal in a notoriously treatment-resistant indication, likely to accelerate M&A interest and pipeline repositioning toward RAS-targeted agents.